Lorente Leonardo, Martín María M, Vidal Pablo, Rebollo Sergio, Ostabal María I, Solé-Violán Jordi
Crit Care. 2014 Oct 17;18(5):564. doi: 10.1186/s13054-014-0564-3.
Best clinical practice for patients with suspected catheter-related infection (CRI) remains unclear according to the latest Infectious Diseases Society of America (IDSA) guidelines. Thus, the objective of this study was to analyze clinical practice concerning the central venous catheter (CVC) and its impact on prognosis in patients with suspected CRI.
We performed a prospective, multicenter, observational study in 18 Spanish Intensive Care Units (ICUs). Inclusion criteria were patients with CVC and suspected CRI. The following exclusion criteria were used: age less than 18 years; pregnancy; lactation; human immunodeficiency virus; neutropenia; solid or haematological tumor; immunosuppressive or radiation therapy; transplanted organ; intravascular foreign body; haemodynamic instability; suppuration or frank erythema/induration at the insertion site of the CVC, and patients with bacteremia or fungemia. The end-point of the study was mortality at 30 days of CRI suspicion.
The study included 384 patients. In 214 (55.8%) patients, CVC was removed at the moment of CRI suspicion, in 114 (29.7%) CVC was removed later and in 56 (14.6%) CVC was not removed. We did not find significant differences between survivors (n =311) and non-survivors (n =73) at 30 days according to CVC decision (P =0.26). The rate of confirmed catheter-related bloodstream infection (CRBSI) was higher in survivors than in non-survivors (14.5% versus 4.1%; P =0.02). Mortality rate was lower in patients with CRBSI than in the group of patients whose clinical symptoms were due to other causes (3/48 (6.25%) versus 70/336 (20.8%); P =0.02). We did not find significant differences in mortality in patients with confirmed CRBSI according to CVC removal at the moment of CRI suspicion (n =38) or later (n =10) (7.9% versus 0; P =0.99).
In patients with suspected CRI, immediate CVC removal may be not necessary in all patients. Other aspects should be taken into account in the decision-making, such as vascular accessibility, the risk of mechanical complications during new cannulation that may be life-threatening, and the possibility that the CVC may not be the origin of the suspected CRI.
根据美国传染病学会(IDSA)的最新指南,对于疑似导管相关感染(CRI)患者的最佳临床实践仍不明确。因此,本研究的目的是分析关于中心静脉导管(CVC)的临床实践及其对疑似CRI患者预后的影响。
我们在18个西班牙重症监护病房(ICU)进行了一项前瞻性、多中心、观察性研究。纳入标准为患有CVC且疑似CRI的患者。采用以下排除标准:年龄小于18岁;怀孕;哺乳期;人类免疫缺陷病毒;中性粒细胞减少症;实体或血液系统肿瘤;免疫抑制或放射治疗;器官移植;血管内异物;血流动力学不稳定;CVC插入部位有化脓或明显红斑/硬结,以及患有菌血症或真菌血症的患者。研究的终点是CRI疑似发生后30天的死亡率。
该研究纳入了384例患者。在214例(55.8%)患者中,在CRI疑似发生时拔除了CVC,114例(29.7%)患者后来拔除了CVC,56例(14.6%)患者未拔除CVC。根据CVC的处理决定,在30天时幸存者(n =311)和非幸存者(n =73)之间未发现显著差异(P =0.26)。幸存者中确诊的导管相关血流感染(CRBSI)发生率高于非幸存者(14.5%对4.1%;P =0.02)。CRBSI患者的死亡率低于临床症状由其他原因引起的患者组(3/48(6.25%)对70/336(20.8%);P =0.02)。根据CRI疑似发生时(n =38)或之后(n =10)是否拔除CVC,确诊CRBSI患者的死亡率未发现显著差异(7.9%对0;P =0.99)。
对于疑似CRI的患者,并非所有患者都需要立即拔除CVC。在决策时应考虑其他方面,如血管通路、新插管过程中可能危及生命的机械并发症风险,以及CVC可能不是疑似CRI来源的可能性。